Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol

“…On the basis of multivariate analysis, Mori et al 14 reported that being young and having an oxaliplatinfree interval were independent risk factors, whereas Shao et al 11 reported higher oxaliplatin dose per infusion as an independent risk factor. Moreover, a recent study 13 found that a lower dose of dexamethasone (o20 mg) could be a positive risk factor. In our study, all patients except one were taking the same dose of dexamethasone (6.6 mg) as premedication; however, the aforementioned variables that were previously reported as potential risk factors were not significant in our study.…”

“…To our knowledge, only 4 investigations have previously attempted to identify potential predictive factors by multivariate analysis. [11][12][13][14] Kim et al 12,13 analyzed the possible association between oxaliplatin-related HSR and clinical characteristics and found that younger patients, females, and patients receiving oxaliplatin in salvage regimens were more likely to experience oxaliplatin-related HSR. On the basis of multivariate analysis, Mori et al 14 reported that being young and having an oxaliplatinfree interval were independent risk factors, whereas Shao et al 11 reported higher oxaliplatin dose per infusion as an independent risk factor.…”

“…Subsequently, a bolus dose of 5-FU (400 mg/m 2 ) was injected intravenously, followed by infusion of 5-FU (2400 mg/m 2 ) for 46 hours. This regimen was repeated every 2 weeks), 48 patients received capecitabine plus oxaliplatin (XELOX; capecitabine of 1,000 mg/m 2 (orally administered twice a day on days [1][2][3][4][5][6][7][8][9][10][11][12][13][14] and oxaliplatin at 130 mg/m 2 (on day 1, as intravenous for 2 hours). The regimens were repeated every 3 weeks after initiation of the first cycle), and 17 patients received other regimens.…”

“…Although oxaliplatin-related HSR is a pressing concern, little information is available on the risk factors involved, and only 4 known studies have explored this issue by multivariate analysis. [11][12][13][14] As a result, there are no confirmed risk factors for oxaliplatin-related HSR that can be effectively applied in clinical practice.…”

A New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach

“…In Japan, one study revealed that serum lactate dehydrogenase (LDH) levels at the beginning of chemotherapy might predict IHSRs to oxaliplatin [20], and a Korean study suggested that the amount of dexamethasone used as premedication could predict IHSRs [21]. Further studies, however, are needed to confirm the reliability of these factors.…”